{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:00Z","timestamp":1707524580037},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,27]]},"DOI":"10.7759\/cureus.22654","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T17:15:16Z","timestamp":1645982116000},"source":"Crossref","is-referenced-by-count":0,"title":["Statin-Related Necrotizing Autoimmune Myositis: More Than Myalgia"],"prefix":"10.7759","author":[{"given":"William J","family":"Scheuing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frany B","family":"Dadhania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adegbenga A","family":"Bankole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy6020043","article-title":"Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice","volume":"6","author":"Fuentes AV","year":"2018","unstructured":"Fuentes AV, Pineda MD, Venkata KC. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. Pharmacy (Basel). 2018, 6:43. 10.3390\/pharmacy6020043","journal-title":"Pharmacy (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase","volume":"389","author":"Gupta A","year":"2017","unstructured":"Gupta A, Thompson D, Whitehouse A, et al.. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017, 389:2473-81. 10.1016\/S0140-6736(17)31075-9","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2174\/1570161116666180817155058","article-title":"The pleiotropic effects of statins - from coronary artery disease and stroke to atrial fibrillation and ventricular tachyarrhythmia","volume":"17","author":"Oesterle A","year":"2019","unstructured":"Oesterle A, Liao JK. The pleiotropic effects of statins - from coronary artery disease and stroke to atrial fibrillation and ventricular tachyarrhythmia. Curr Vasc Pharmacol. 2019, 17:222-32. 10.2174\/1570161116666180817155058","journal-title":"Curr Vasc Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.05.002","article-title":"The nocebo effect in the context of statin intolerance","volume":"10","author":"Tobert JA","year":"2016","unstructured":"Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol. 2016, 10:739-47. 10.1016\/j.jacl.2016.05.002","journal-title":"J Clin Lipidol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2019.01.018","article-title":"Statins, myalgia, and rhabdomyolysis","volume":"87","author":"Tournadre A","year":"2020","unstructured":"Tournadre A. Statins, myalgia, and rhabdomyolysis. Joint Bone Spine. 2020, 87:37-42. 10.1016\/j.jbspin.2019.01.018","journal-title":"Joint Bone Spine"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170282","article-title":"Anti-HMGCR myopathy","volume":"5","author":"Mohassel P","year":"2018","unstructured":"Mohassel P, Mammen AL. Anti-HMGCR myopathy. J Neuromuscul Dis. 2018, 5:11-20. 10.3233\/JND-170282","journal-title":"J Neuromuscul Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen AL","year":"2016","unstructured":"Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016, 374:664-9. 10.1056\/NEJMra1515161","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen AL","year":"2011","unstructured":"Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, Casciola-Rosen LA. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011, 63:713-21. 10.1002\/art.30156","journal-title":"Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham M","year":"2007","unstructured":"Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007, 17:194-200. 10.1016\/j.nmd.2006.10.007","journal-title":"Neuromuscul Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.1998.02.349","article-title":"Corticosteroids in rheumatic disease. Understanding their effects is key to their use","volume":"103","author":"van Vollenhoven RF","year":"1998","unstructured":"van Vollenhoven RF. Corticosteroids in rheumatic disease. Understanding their effects is key to their use. Postgrad Med. 1998, 103:137-42. 10.3810\/pgm.1998.02.349","journal-title":"Postgrad Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen AL","year":"2015","unstructured":"Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015, 373:1680-2. 10.1056\/NEJMc1506163","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171495","article-title":"Rituximab in the treatment of refractory anti-HMGCR immune-mediated necrotizing myopathy","volume":"46","author":"Landon-Cardinal O","year":"2019","unstructured":"Landon-Cardinal O, Allenbach Y, Soulages A, et al.. Rituximab in the treatment of refractory anti-HMGCR immune-mediated necrotizing myopathy. J Rheumatol. 2019, 46:623-7. 10.3899\/jrheum.171495","journal-title":"J Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer A","year":"2020","unstructured":"Meyer A, Troyanov Y, Drouin J, et al.. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther. 2020, 22:5. 10.1186\/s13075-019-2093-6","journal-title":"Arthritis Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S197941","article-title":"Statin-associated autoimmune myopathy: current perspectives","volume":"16","author":"Tiniakou E","year":"2020","unstructured":"Tiniakou E. Statin-associated autoimmune myopathy: current perspectives. Ther Clin Risk Manag. 2020, 16:483-92. 10.2147\/TCRM.S197941","journal-title":"Ther Clin Risk Manag"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study","volume":"15","author":"Musset L","year":"2016","unstructured":"Musset L, Allenbach Y, Benveniste O, et al.. Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study. Autoimmun Rev. 2016, 15:983-93. 10.1016\/j.autrev.2016.07.023","journal-title":"Autoimmun Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/82582-statin-related-necrotizing-autoimmune-myositis-more-than-myalgia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:57Z","timestamp":1707507537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/82582-statin-related-necrotizing-autoimmune-myositis-more-than-myalgia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,27]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.22654","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,27]]}}}